文献速递腹部介入CT

形态学分组在评估肝转移瘤消融放疗疗效中的附加价值

The additive value of morphologic grouping in assessing treatment response to ablative radiation therapy in liver metastases.
PubMed 文献 · Abdom Radiol (NY) · 2025-09-20

回顾性单中心研究纳入33例接受消融放疗的肝转移瘤患者,比较RECIST 1.1与改良形态学分组评估疗效。改良形态学分组在第二、三、四次随访时与持久局部控制相关,RECIST 1.1仅在第三、四次随访时相关;两者均与总生存无关。

要点

  • 改良形态学分组在第二次随访即与持久局部控制相关,可能有助于早期识别疗效。
  • RECIST 1.1仅在第三、四次随访时与持久局部控制相关。
  • 两种评估方法与总生存均无显著关联(P=0.15-0.24)。

核心结论

  • 基于改良形态学分组的疗效评估可能较RECIST 1.1更早识别肝转移瘤消融放疗后的持久局部控制,尤其在早期随访时间点。

研究设计与样本

  • 回顾性单中心研究,纳入2017年1月至2021年11月连续33例接受消融放疗的肝转移瘤患者,均至少接受两次腹部增强CT随访;两名腹部放射科医师独立依据RECIST 1.1和改良形态学分组(基于德克萨斯大学MD安德森癌症中心原提案的改良版)评估基线与随访扫描。

诊断标准与关键数值

  • 持久局部控制定义为放疗后治疗肿瘤缩小且随访影像稳定超过1年、无疾病进展。
  • 改良形态学分组在第二、三、四次随访与持久局部控制相关:阅片者1 P=0.009、<0.001、<0.001,阅片者2 P=0.003、<0.001、<0.001。
  • RECIST 1.1在第三、四次随访与持久局部控制相关:阅片者1 P=0.007、0.004,阅片者2 P=0.008、0.01。
  • 两种方法与总生存均无显著关联(P=0.15-0.24)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the utility of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and a modified version of previously proposed morphologic grouping in assessing treatment response to ablative radiotherapy in liver metastases.

METHODS: This retrospective, single-institution study included consecutive patients with liver metastases who were treated with ablative radiotherapy and who underwent at least two follow-up abdominal contrast-enhanced CT scans from January 2017-November 2021. Two abdominal radiologists independently assessed baseline and follow-up scans based on RECIST 1.1 and a modified version of morphologic grouping originally proposed by the University of Texas MD Anderson Cancer Center. The association between each response assessment method with durable local control (i.e., decreased treated tumor size after radiation and stability over > 1 year on follow-up imaging with no progression of disease) and overall survival was assessed using multivariable generalized estimating equations and the univariable Cox proportional hazards model, respectively.

RESULTS: Of 33 patients (17 men and 16 women; mean age at baseline, 63 years (range, 28-84); median follow-up, 368 days), 19/33 (58%) had durable local control. Modified morphologic grouping at the second, third, and fourth follow-up timepoints was associated with durable local control (P = 0.009, < 0.001, < 0.001, for Reader 1, and 0.003, < 0.001, < 0.001 for Reader 2). RECIST 1.1 at the third and fourth follow-up timepoints was associated with durable local control (P = 0.007 and 0.004 for Reader 1, and 0.008 and 0.01 for Reader 2). Neither was associated with overall survival (P = 0.15-0.24).

CONCLUSION: Modified morphologic grouping-based response assessment of liver metastases treated with ablative radiotherapy may enable early detection of durable local control when compared to RECIST 1.1, especially at early follow-up timepoints.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. El Homsi M, Hamdan D, Ahmed FS, et al. The additive value of morphologic grouping in assessing treatment response to ablative radiation therapy in liver metastases. Abdom Radiol (NY). 2025. PMID: 40974478. doi:10.1007/s00261-025-05200-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。